{"classes":[{"categories":[{"measurements":[{"comment":"Mean and standard deviation were not calculable as the values were below the limit of quantitation","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Mean and standard deviation were not calculable as the values were below the limit of quantitation","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Mean and standard deviation were not calculable as the values were below the limit of quantitation","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Predose: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"245000","value":"435000"},{"groupId":"OG001","spread":"182000","value":"303000"},{"groupId":"OG002","spread":"115000","value":"421000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Predose: Cycle 1 Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"233000","value":"621000"},{"groupId":"OG001","spread":"293000","value":"713000"},{"groupId":"OG002","spread":"274000","value":"675000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Predose: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"399000","value":"853000"},{"groupId":"OG001","spread":"365000","value":"739000"},{"groupId":"OG002","spread":"238000","value":"847000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Predose: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82700","value":"694000"},{"comment":"Standard deviation was not calculable due to less than 3 participants available for analysis.","groupId":"OG001","spread":"NA","value":"5540"},{"groupId":"OG002","spread":"161000","value":"459000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Predose: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"186000","value":"517000"},{"groupId":"OG001","spread":"142000","value":"373000"},{"groupId":"OG002","spread":"90700","value":"448000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Predose: Cycle 5 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculable due to less than 3 participants available for analysis.","groupId":"OG000","spread":"NA","value":"332000"},{"groupId":"OG001","spread":"153000","value":"307000"},{"groupId":"OG002","spread":"140000","value":"376000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Predose: Cycle 7 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculable due to less than 3 participants available for analysis.","groupId":"OG000","spread":"NA","value":"336000"},{"groupId":"OG002","spread":"345000","value":"361000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Predose: Cycle 10 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculable due to less than 3 participants available for analysis.","groupId":"OG000","spread":"NA","value":"295000"},{"comment":"Standard deviation was not calculable due to less than 3 participants available for analysis.","groupId":"OG002","spread":"NA","value":"624000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Predose: Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"337000","value":"445000"},{"groupId":"OG001","spread":"131000","value":"179000"},{"groupId":"OG002","spread":"34000","value":"86000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Anytime: Last sample collection day: Up to Day 358"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Arm 1: Magrolimab+Daratumumab; Arm 2: Magrolimab+Pomalidomide+Dexamethasone; Arm 3: Magrolimab+Carfilzomib+Dexamethasone.","dispersionType":"Standard Deviation","groups":[{"description":"Participants in Safety Run-in and Dose-expansion period with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI received magrolimab IV 1 mg/kg on Day 1 and 30 mg/kg on Days 8, 15, 22, 29 of Cycle 1; 30 mg/kg every week on Days 1, 8, 15, 22 of Cycle 2; 30 mg/kg on Days 1, 15 from Cycle 3 onwards.\n\nParticipants also received daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1; Days 1, 8, 15, 22 of Cycle 2; and Days 1, 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days).","id":"OG000","title":"Magrolimab+Daratumumab"},{"description":"Participants in Safety Run-in and Dose-expansion period with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI received magrolimab IV 1 mg/kg on Day 1 and 30 mg/kg on Days 8, 15, 22, 29 of Cycle 1; 30 mg/kg every week on Days 1, 8, 15, 22 of Cycle 2; 30 mg/kg on Days 1, 15 from Cycle 3 onwards.\n\nParticipants also received pomalidomide orally 4 mg on Days 1 to 21 (daily) of Cycle 1 and onward and dexamethasone orally 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1; Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).","id":"OG001","title":"Magrolimab+Pomalidomide+Dexamethasone"},{"description":"Participants in Safety Run-in and Dose-expansion period with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI received magrolimab IV 1 mg/kg on Day 1 and 30 mg/kg on Days 8, 15, 22, 29 of Cycle 1; 30 mg/kg every week on Days 1, 8, 15, 22 of Cycle 2; 30 mg/kg on Days 1, 15 from Cycle 3 onwards.\n\nParticipants also received carfilzomib IV 20 mg/m\\^2 on Days 8, 15, 22 of Cycle 1; Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m\\^2 was tolerated after Cycle 1, Day 8, the dose was escalated to 70 mg/m\\^2 on Cycle 1, Day 15 and thereafter) and dexamethasone orally or IV 40 mg on Days 8, 15, 22, 29 of Cycle 1; Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days).","id":"OG002","title":"Magrolimab+Carfilzomib+Dexamethasone"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetic Analysis Set included all participants who received ≥ 1 dose of magrolimab and had ≥ 1 measurable posttreatment serum concentration of magrolimab. Participants with available data were analyzed.\n\nAs all participants were dosed with same dose of magrolimab, per prespecified analysis, data for Safety Run-in and corresponding Dose-expansion cohorts were combined for all 3 arms.","reportingStatus":"POSTED","timeFrame":"Arm 1, 2, 3: Predose: Days 1 and 22 of Cycle 1, Day 1 of Cycles 2, 3, 4, 5, 7, and on last sample collection day (anytime; up to Day 358); Arm 1 and 3: Predose: Day 1 of Cycles 10 and 13","title":"Serum Concentration of Magrolimab","type":"SECONDARY","unitOfMeasure":"ng/mL"}